SALEM, Mass., April 29 /PRNewswire/ -- LaVoie Group, a life science-focused strategic communications agency, announced today that it has been selected as public relations agency of record by therapeutic vaccine development company, Profectus BioSciences, Inc.
Donna L. LaVoie, President & CEO of LaVoie Group, commented, "We are delighted to represent Profectus during an important stage in the company's clinical development. We look forward to working with them to communicate their message to appropriate investors, media, pharmaceutical partners and physicians."
Shawn Patrick O'Brien, Chief Executive Officer, commented, "Profectus BioSciences has a strong value proposition since the vaccine sector has emerged as a key revenue generator for big pharma with favorable legislation, relatively low development risk, exemplary commercial success of several blockbuster vaccines, and therapeutic vaccines being more attractive than preventative vaccines. By retaining LaVoie Group, I am confident that we will deliver our message more effectively to our key constituencies."
About Profectus BioSciences, Inc.
Profectus BioSciences is an innovative research and development vaccine company devoted to advancing the treatment and prevention of chronic viral diseases. The Profectus proprietary vaccine design approach combines its pDNA and rVSV platforms via a unique prime boost strategy to enhance immune response. Profectus' broad product pipeline will address Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Human Papilloma Virus (HPV) and Herpes Simplex Virus (HSV).
The Profectus portfolio has received over $100 million in funding from multiple sources including National Institutes of Health (NIH), Cross Atlantic Capital Partners and through private investments. Profectus deploys these resources in support of its proprietary prime boost vaccines and its anti-inflammatory sma
|SOURCE LaVoie Group|
Copyright©2009 PR Newswire.
All rights reserved